title: Bone metastases and bone loss medical treatment in prostate cancer patients.
abstract: Prostate cancer is a malignancy in urology with the highest incidence metastasize to the bone up to 70%. The incidence of skeletal related event (SRE) by 46.1% such as severe pain, pathologic fractures, spinal compression syndrome and hypercalcemia, with a consequence of higher inpatient care and worsen the patient's prognosis. Androgen deprivation therapy (ADT) as a metastatic prostate cancer treatment itself causes an osteopenia or osteoporosis. Bisphosphonate inhibits normal and pathologic osteoclast-mediated bone resorption by several mechanisms. Denosumab is the latest treatment option in bone metastases. Multi-study shows the efficacy of denosumab is better than zoledronic acid for SRE prevention. Adverse events between denosumab and bisphosphonate are comparable.
authors.affiliation: Department of Urology, Faculty of Medicine, Padjajaran University - Hasan Sadikin Hospital. Jl. Pasteur no 38 Bandung, Indonesia. safriadif@yahoo.com
authors.forename: Ferry
authors.initials: F
authors.lastname: Safriadi
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000503:physiopathology* / Q000556:secondary / Q000628:therapy*; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects; D006801:Humans; D008297:Male; D009919:Orchiectomy / Q000009:adverse effects; D010024:Osteoporosis / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000726:Androgen Antagonists; D050071:Bone Density Conservation Agents; D007987:Gonadotropin-Releasing Hormone